- Top of page
- Epidemiology of diabetes mellitus and skin cancer
- Perspectives from epidemiological studies: metformin is chemoprevention agent
- Perspectives from basic science: metformin is a potential skin cancer chemoprevention agent?
- Hypothesis: metformin targets skin cancer stem cells (CSCs)
- Author contributions
- Conflict of interest
- Supporting Information
Type II diabetes is associated with increased prevalence of cancer including both melanoma and squamous cell carcinoma (SCC) of the skin. Emerging evidence from epidemiological studies suggest that diabetic patients on metformin have a lower risk of cancer incidence and mortality in a broad range of neoplasms. In both melanoma and SCC, populations of cancer stem cells (CSC) contribute to tumor initiation and metastasis. We propose that metformin constitutes a new class of targeted therapy that acts on the skin CSC diaspora. We posit that metformin selectively and simultaneously targets CSCs of the primary tumor as well as in metastatic niches thereby disrupting the dynamic dispersal of circulating CSCs between the primary tumor and metastatic site. This hypothesis suggests a new concept in dermato-oncology that treatment of type II diabetes and prevention of skin cancer are two sides of the same coin.